Biomedical Engineering Reference
In-Depth Information
Hunter J, Hirst BH (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related
drug efflux systems in limiting oral drug absorption. . Adv Drug Deliv Rev 25 (2-3):129-157.
doi:10.1016/S0169-409X(97)00497-3
Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH (1993) Functional expression of
P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine
secretion and interaction with modulators. J Biol Chem 268 (20):14991-14997
Hussain N, Jaitley V, Florence AT (2001) Recent advances in the understanding of uptake of
microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev 50 (1-2):107-142.
doi:S0169-409X(01)00152-1 [pii]
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multi-
drug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53
(19):4595-4602
Irache JM, Salman HH, Gomez S, Espuelas S, Gamazo C (2010) Poly(anhydride) nanoparticles
as adjuvants for mucosal vaccination. Front Biosci (Schol Ed) 2:876-890. doi:108 [pii]
IRSHAD S (2010) Considerations when choosing oral chemotherapy: identifying and responding to
patient need. European Journal of Cancer Care 19:5-11. doi:10.1111/j.1365-2354.2010.01199.x
Ishikawa M, Yoshii H, Furuta T (2005) Interaction of modified cyclodextrins with cytochrome
P-450. Biosci Biotechnol Biochem 69 (1):246-248. doi:JST.JSTAGE/bbb/69.246 [pii]
Jepson MA, Clark MA, Hirst BH (2004) M cell targeting by lectins: a strategy for mucosal vac-
cination and drug delivery. Adv Drug Deliv Rev 56 (4):511-525. doi:10.1016/j.addr.2003.10.018
S0169409X03002333 [pii]
Kalinski P (2009) Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2,
3 and 4. Curr Opin Investig Drugs 10 (6):526-535
Kaukonen AM, Boyd BJ, Porter CJ, Charman WN (2004) Drug solubilization behavior
during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res 21
(2):245-253
Kawata S, Minami Y, Tarui S, Marunaka T, Okamoto M, Yamano T (1984) Cytochrome P-450-
dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. Jpn
J Pharmacol 36 (1):43-49
Kivisto KT, Niemi M, Fromm MF (2004) Functional interaction of intestinal CYP3A4 and
P-glycoprotein. Fundam Clin Pharmacol 18 (6):621-626. doi:FCP291 [pii] 10.1111/j.1472-8206.
2004.00291.x
Krishnamachari Y, Geary SM, Lemke CD, Salem AK (2010) Nanoparticle Delivery Systems in
Cancer Vaccines. Pharm Res. doi:10.1007/s11095-010-0241-4
Kruijtzer CM, Beijnen JH, Schellens JH (2002) Improvement of oral drug treatment by temporary
inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver:
an overview. Oncologist 7 (6):516-530
Kuppens IE, Breedveld P, Beijnen JH, Schellens JH (2005) Modulation of oral drug bioavailability:
from preclinical mechanism to therapeutic application. Cancer Invest 23 (5):443-464
Lasaro MO, Ertl HC (2010) Targeting inhibitory pathways in cancer immunotherapy. Curr Opin
Immunol 22 (3):385-390. doi:S0952-7915(10)00069-5 [pii] 10.1016/j.coi.2010.04.005
Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications.
Clin Pharmacokinet 35 (5):361-390
Liu G, Franssen E, Fitch M, Warner E (1997) Patient preference for oral versus intravenous pallia-
tive chemotherapy. J Clin Oncol 24 (15):110-115
Lo YL (2003) Relationships between the hydrophilic-lipophilic balance values of pharmaceutical
excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
J Control Release 90 (1):37-48. doi:S0168365903001639 [pii]
Malik B, Goyal AK, Mangal S, Zakir F, Vyas SP (2010) Implication of gut immunology in the
design of oral vaccines. Curr Mol Med 10 (1):47-70. doi:CMM # 16 [pii]
Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H
(1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates
5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer
tissue. Eur J Cancer 34 (8):1274-1281. doi:S0959804998000586 [pii]
Search WWH ::




Custom Search